Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director | September 22, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mineralys Therapeutics, Inc.
Report date September 22, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 7,805,718 |
Reported balance
After 2026-09-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-22 · Sale · Disposed 104,320 · Balance 7,805,718 F1: Represents shares of common stock sold by Catalys Pacific Fund, LP. See footnote (3). F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.700 to $28.905. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Represents shares of common stock held of record by Catalys Pacific Fund, LP. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP, and Mr. Slingsby is the managing partner of Catalys Pacific, LLC. Accordingly, Mr. Slingsby may be deemed to share voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Mr. Slingsby disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock sold by Catalys Pacific Fund, LP. See footnote (3).
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.700 to $28.905. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Represents shares of common stock held of record by Catalys Pacific Fund, LP. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP, and Mr. Slingsby is the managing partner of Catalys Pacific, LLC. Accordingly, Mr. Slingsby may be deemed to share voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Mr. Slingsby disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 25, 2026 01:49 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 104,320 | $28.81 | $3,005,302.72 |
DisclosureSEC source: 0001963901-26-000003 · wk-form4_1790300978.xml · nonDerivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,805,718 F1 · kind: Represents shares of common stock sold by Catalys Pacific Fund, LP. See footnote (3). F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.700 to $28.905. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares of common stock held of record by Catalys Pacific Fund, LP. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP, and Mr. Slingsby is the managing partner of Catalys Pacific, LLC. Accordingly, Mr. Slingsby may be deemed to share voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Mr. Slingsby disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 8,300 | $0.00 Strike: $28.06 | $0.00 |
DisclosureSEC source: 0001933414-26-000041 · wk-form4_1771634836.xml · derivative · entry 6 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2036-02-19 F2 · kind: Represents stock options or RSUs transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F4 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. F3 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 8,300 | $0.00 Strike: $28.06 | $0.00 |
DisclosureSEC source: 0001933414-26-000041 · wk-form4_1771634836.xml · derivative · entry 5 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,300 shares Expires 2036-02-19 F2 · kind: Represents stock options or RSUs transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F4 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 8,300 | $0.00 Strike: $28.06 | $0.00 |
DisclosureSEC source: 0001933414-26-000041 · wk-form4_1771634836.xml · derivative · entry 4 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2036-02-19 F4 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001933414-26-000041 · wk-form4_1771634836.xml · nonDerivative · entry 3 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,910,038 F2 · kind: Represents stock options or RSUs transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. F3 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001933414-26-000041 · wk-form4_1771634836.xml · nonDerivative · entry 2 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: Represents stock options or RSUs transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001933414-26-000041 · wk-form4_1771634836.xml · nonDerivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 18:07 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 1,000,000 | $43.35 | $43,350,000.00 |
DisclosureSEC source: 0001933414-25-000156 · wk-form4_1763766476.xml · nonDerivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 7,903,838 F1 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 13, 2025 Filed Apr 25, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 259,259 | $13.50 | $3,499,996.50 |
DisclosureSEC source: 0001933414-25-000052 · wk-form4_1745622111.xml · nonDerivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 8,903,838 F1 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 13, 2025 Filed Feb 24, 2025 18:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 32,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000017 · wk-form4_1740441556.xml · derivative · entry 3 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 32,900 Underlying: Common Stock · 32,900 shares Expires 2035-02-13 F2 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. F3 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 13, 2025 Filed Feb 24, 2025 18:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 32,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000017 · wk-form4_1740441556.xml · derivative · entry 2 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,900 shares Expires 2035-02-13 F2 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 24, 2025 18:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 32,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000017 · wk-form4_1740441556.xml · derivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,900 Underlying: Common Stock · 32,900 shares Expires 2035-02-13 F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 21:45 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 550,000 | $13.05 | $7,177,500.00 |
DisclosureSEC source: 0001628280-24-033205 · wk-form4_1722044745.xml · nonDerivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 8,644,579 F1 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 22, 2024 Filed May 23, 2024 16:21 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 22,000 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001933414-24-000019 · wk-form4_1716495657.xml · derivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting. Read SEC document |
| May 22, 2024 Filed Jan 7, 2025 17:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 22,000 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001933414-25-000001 · wk-form4_1736290727.xml · derivative · entry 2 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-05-22 F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F2 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting. F3 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 22, 2024 Filed Jan 7, 2025 17:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 22,000 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001933414-25-000001 · wk-form4_1736290727.xml · derivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires 2034-05-22 F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. F2 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 08:55 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 88,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001933414-23-000043 · wf-form4_168933930313513.xml · derivative · entry 2 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2033-02-09 F3 · kind: Represents stock options transferred pursuant to option transfer agreements between Catalys Pacific Fund, LP and each of Brian Taylor Slingsby and Takeshi Takahashi. F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023. F4 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 08:55 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | OtherStock Option · Derivative | 44,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001933414-23-000043 · wf-form4_168933930313513.xml · derivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2033-02-09 F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between Brian Taylor Slingsby and Catalys Pacific Fund, LP. F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 16:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionSeries B Preferred Stock · Derivative | 2,142,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003922 · wf-form4_167658442850041.xml · derivative · entry 4 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,142,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F2 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 16:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionSeries A Preferred Stock · Derivative | 2,171,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003922 · wf-form4_167658442850041.xml · derivative · entry 3 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,171,342 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F2 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 16:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 250,000 | $16.00 | $4,000,000.00 |
DisclosureSEC source: 0001628280-23-003922 · wf-form4_167658442850041.xml · nonDerivative · entry 2 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,194,579 F2 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 16:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionCommon Stock | 4,314,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-003922 · wf-form4_167658442850041.xml · nonDerivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,944,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering. F2 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:03 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 44,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003431 · wf-form4_167634020870900.xml · derivative · entry 1 Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2033-02-09 F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.